vulvar

Imiquimod (R 837) is an immune response modifier and a toll-like receptor 7 (TLR7) agonist with antiviral and antitumor effects. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and is commonly employed to induce psoriasis models.

SDZ 281-977 is a derivative of Lavendustin A, an EGF receptor tyrosine kinase inhibitor.

CID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma, breast cancer and bone cancer. It can be used to study hypertension, Alzheimer's disease and arteriosclerosis.

Kahalalide F is a novel marine-derived antitumor agent known for inhibiting DNA synthesis. It exhibits cytotoxicity that is not correlated with the expression levels of the multidrug resistance gene MDR1 or the tyrosine kinase HER2/NEU, and is only slightly related to the expression of the anti-apoptotic protein BCL-2. Kahalalide F hinders the PI3K-Akt signaling pathway by depleting ErbB3. Its effects are rapidly activated with short pulse treatments. The compound primarily induces cell death through oncosis (cellular swelling) in tumor cells. Kahalalide F can be utilized in studies of prostate cancer, breast cancer, vulvar cancer, and non-small cell lung cancer.

Ospemifene (FC-1271a) is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.